SERIES [A/B] COMMON STOCK PURCHASE WARRANT NOVUS THERAPEUTICS, INC.Novus Therapeutics, Inc. • May 2nd, 2019 • Pharmaceutical preparations
THIS SERIES [A/B] COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on ________1 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Novus Therapeutics, Inc., a Delaware corporation (the “Company”), up to ______ shares of Common Stock (the shares of Common Stock issuable upon exercise hereof being referred to as the “Warrant Shares”) [;provided, however, the exercisability of this Series B Warrant shall vest ratably from time to time in proportion to the Holder’s (or its permitted assigns) exercise in cash of the Series A Common Stock Purchase Warrant as compared with all Series A Common Stock Purchase Warrants issued to the Holder on the Initial Exercise
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • May 2nd, 2019 • Novus Therapeutics, Inc. • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of April 30, 2019, (the “Effective Date”) between Novus Therapeutics, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT NOVUS THERAPEUTICS, INC.Novus Therapeutics, Inc. • May 2nd, 2019 • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on (the “Termination Date”) but not thereafter, to subscribe for and purchase from Novus Therapeutics, Inc., a Delaware corporation (the “Company”), up to shares of Common Stock (the shares of Common Stock issuable upon exercise hereof being referred to as the “Warrant Shares”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is issued pursuant to that certain Engagement Agreement, by and between the Company and H.C. Wainwright & Co., LLC, dated as of April 22, 2019, and amended on April 29, 2019.
